Merck obtains exclusive global rights for LM-299, a clinical investigational bispecific antibody targeting PD-1 and VEGF, from LaNova Medicines Ltd.

Tune Therapeutics Enters Clinical Arena with TUNE-401: A Novel Epigenetic Silencer Targeting Hepatitis B.

Tirzepatide treatment in obese or overweight adults with pre-diabetes led to lasting weight reduction, with almost 99% staying free of diabetes after 176 weeks.

MoonLake Immunotherapeutics has launched Phase 3 of the IZAR program for the Nanobody® sonelokimab in individuals suffering from active psoriatic arthritis.

Gan & Lee Pharmaceuticals reported favorable Phase 1 outcomes for its oral GLP-1 receptor agonist, GZR18 tablet, in healthy subjects, showing a weight loss of 4.16% over two weeks.

Pimicotinib meaningfully enhanced results for patients with tenosynovial giant cell tumor in an international Phase III study.

New BLA for Datopotamab Deruxtecan filed in the U.S. for fast-track approval in patients with advanced EGFR-mutated non-small cell lung cancer who have received prior treatment.

Apollo Therapeutics has secured an exclusive license from Sunshine Lake Pharma for a clinical-stage dual receptor agonist targeting FGF21 and GLP-1.

KOSELUGO® (Selumetinib) Shows Significant Improvement in Response Rate Compared to Placebo in Adults with Symptomatic Neurofibromatosis Type 1.

Autolus Therapeutics has received FDA approval for AUCATZYL® (obecabtagene autoleucel-obe-cel) for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

Marengo shares encouraging initial human safety, tolerability, and clinical activity results for its lead candidate, Invikafusp Alfa (STAR0602).

STORM Therapeutics reveals that it shared encouraging findings from its Phase 1 clinical trial of STC-15, an inhibitor targeting METTL3 RNA methyltransferase.